Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CPA1 | P15085 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5244700 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CYP2C19LMNACNR1CPA1 | |
| SCHEMBL14338548 | 0.94 | ALDH1A1 (0.53) | ALDH1A1CYP2C19LMNACNR1MEN1 | |
| SCHEMBL5410414 | 0.86 | ALDH1A1 (0.48) | ALDH1A1CYP2C19LMNACNR1CPA1 | |
| SCHEMBL5410420 | 0.86 | ALDH1A1 (0.48) | ALDH1A1CYP2C19LMNACNR1CPA1 | |
| SCHEMBL5351216 | 0.85 | ALDH1A1 (0.59) | ALDH1A1CYP2C19LMNAMEN1KMT2A | |
| SCHEMBL5351226 | 0.85 | ALDH1A1 (0.59) | ALDH1A1CYP2C19LMNAMEN1KMT2A | |
| SCHEMBL5402301 | 0.83 | ALDH1A1 (0.46) | ALDH1A1CYP2C19LMNACPA1MEN1 | |
| SCHEMBL5402293 | 0.83 | ALDH1A1 (0.46) | ALDH1A1CYP2C19LMNACPA1MEN1 | |
| SCHEMBL5243446 | 0.83 | ALDH1A1 (0.59) | ALDH1A1CYP2C19LMNACPA1KMT2A | |
| SCHEMBL28334605 | 0.81 | RAB9A (0.43) | ALDH1A1LMNACNR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312335-B2 | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts | BRANDEIS UNIVERSITY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1758899-A1 | ASYMMETRIC MICHAEL AND ALDOL ADDITION USING BIFUNCTIONAL CINCHONA-ALKALOID-BASED CATALYSTS | Brandeis University (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060014956-A1 | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts | BRANDEIS UNIVERSITY | 2006-01-19 | — | — | US | disclosed |
| WO-2005121137-A1 | ASYMMETRIC MICHAEL AND ALDOL ADDITION USING BIFUNCTIONAL CINCHONA-ALKALOID-BASED CATALYSTS | BRANDEIS UNIVERSITY (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014956-A1 | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts | ALDH3A1, NQO1, DERA | ALDH1A1 13/4885CYP2C19 631/4885LMNA 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.